NDAINJECTIONINJECTABLE
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
ULTRAVIST 150 (iopromide) by Bayer is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1995.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRAVIST 150 is an injectable radiographic contrast agent containing iopromide, a non-ionic iodinated compound used to enhance X-ray imaging of blood vessels, organs, and tissues. It works through X-ray contrast activity, improving visualization during diagnostic radiographic procedures. The product is indicated as a general radiographic contrast agent for angiographic and urographic studies.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling potential team consolidation and focus on market defense rather than expansion.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (1)
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
Started Mar 2008
44,920 enrolled
Diagnostic Imaging
Career Relevance
Working on ULTRAVIST 150 at this lifecycle stage offers limited upside opportunity but provides stability in a mature, well-established market. Career growth potential is constrained, with roles focused on margin protection, customer retention, and managed decline rather than expansion or innovation.
Worked on ULTRAVIST 150 at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.